Menu
  • About RedHill
  • Products
  • Partnering
  • Investors
  • News
  • Contact
  • CAREERS
  • Press Releases

     
    Press Releases
      Date Summary View
    Nov 13, 2017
    TEL-AVIV, Israel and RALEIGH, N.C., Nov. 13, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal and inflammatory diseases...
    PDF
    Nov 13, 2017
    RedHill maintains a debt-free balance sheet with $39.6 million in cash1 at the end of the third quarter of 2017In addition, an underwritten public offering of the Company's American Depositary Shares (ADSs) is scheduled to be closed today, November 13, 2017, subject to customary terms and conditions, for aggregate net proceeds of approximately $20....
    PDF
    Nov 9, 2017
    Top-line results are expected to be announced in mid-2018 The Phase III study evaluating RHB-104 for Crohn's disease (MAP US study) is a randomized, double-blind, placebo-controlled study that is evaluating the safety and efficacy of RHB-104 in 331 subjects with moderately to severely active Crohn's disease Worldwide sales of Crohn's disease therap...
    PDF
    Nov 8, 2017
    TEL-AVIV, Israel and RALEIGH, N.C., Nov. 08, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal and inflammatory diseases...
    PDF
    Nov 7, 2017
    TEL-AVIV, Israel and RALEIGH, N.C., Nov. 07, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal and inflammatory diseases...
    PDF
    Nov 6, 2017
    TEL-AVIV, Israel and RALEIGH, N.C., Nov. 06, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal and inflammatory diseases...
    PDF
    Nov 6, 2017
    TEL-AVIV, Israel and RALEIGH, N.C., Nov. 06, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal and inflammatory diseases...
    PDF
    Nov 1, 2017
    RIZAPORT® is a proprietary oral thin-film formulation of rizatriptan for the treatment of acute migrainesA Prescription Drug User Fee Act (PDUFA) date is expected to be set by the FDA for the first half of 2018, if the submission is deemed complete and permits a full reviewRIZAPORT® (5mg and 10mg) was granted marketing authorization in Ge...
    PDF
    Oct 26, 2017
    TEL-AVIV, Israel and RALEIGH, N.C., Oct. 26, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastr...
    PDF
    Oct 23, 2017
    The new patent, covering RHB-104 for relapsing-remitting multiple sclerosis (MS), is expected to be valid until 2032, once grantedEnrollment in the Phase III study with RHB-104 for Crohn's disease to be completed in November 2017 and top-line results expected in Q3/2018A pivotal Phase III study with RHB-104 for Nontuberculous Mycobacteria (NTM) inf...
    PDF
    Page:
    1
    ... NextLast

    Subscribe to press releases